公开(公告)号：US20210388072A1

公开(公告)日：2021-12-16

申请号：US17281874

申请日：2019-10-02

Applicant: OSPEDALE SAN RAFFAELE S.R.L. ,  ENTHERA S.R.L.

Inventor： Paolo FIORINA ,  Francesca D'ADDIO ,  Francesca ZAGARI

IPC: C07K16/22

Abstract: The present invention relates to an antibody or antigen binding fragment thereof that binds specifically to IGFBP3 and does not displace the binding of IGF-I to IGFBP3. The antibody inhibits or reduces the binding of IGFBP3 to the TMEM219 receptor. The invention also relates to methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

公开(公告)号：US20230242649A1

公开(公告)日：2023-08-03

申请号：US17777021

申请日：2020-11-16

Applicant: ENTHERA S.R.L.

Inventor： Paolo FIORINA ,  Giovanni AMABILE ,  Francesca D'ADDIO

IPC: C07K16/28 ,  A61P3/10 ,  C12N15/63

CPC classification number: C07K16/2863 ,  A61P3/10 ,  C12N15/63 ,  C07K2317/565 ,  C07K2317/92 ,  C07K2317/24

Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind specifically to the IGFBP3 receptor, namely TMEM219, to methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

公开(公告)号：US20240368290A1

公开(公告)日：2024-11-07

申请号：US18772062

申请日：2024-07-12

Applicant: ENTHERA S.R.L.

Inventor： Paolo FIORINA ,  Giovanni AMABILE ,  Francesca D'ADDIO

IPC: C07K16/28 ,  A61P3/10 ,  C12N15/63

Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind specifically to the IGFBP3 receptor, namely TMEM219, to methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

公开(公告)号：US20230039165A1

公开(公告)日：2023-02-09

申请号：US17778814

申请日：2020-11-20

Applicant: ENTHERA S.R.L.

Inventor： Giovanni AMABILE ,  Paolo FIORINA ,  Francesca D'ADDIO

IPC: C07K16/22 ,  C12N15/66 ,  A61P7/00

Abstract: The present invention relates to antibodies or antigen binding fragment thereof that binds specifically to IGFBP3. The antibody inhibits or reduces the binding of IGFBP3 to the TMEM219 receptor. The invention also relates to methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.